In this retrospective study, we assessed a cohort of patients with stage I to IV colorectal cancer for CDX2 staining and correlated it with patient demographics; clinicopathologic features; and cancer outcomes including overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS). Here, CDX2 is linked to cancer.